VivoSim prices $4.0 million private placement with single institutional investor

VivoSim Labs, Inc. (Nasdaq: VIVS) announced on July 16, 2026 that it priced a private placement with a single healthcare focused institutional investor. The company agreed to sell 4,705,883 shares of common stock or common stock equivalents, along with warrants for up to 4,705,883 additional shares, at an effective combined price of $0.85 per share, for gross proceeds of approximately $4.0 million before fees and expenses.¹

The warrants carry an exercise price of $0.85 per share, become exercisable immediately after shareholder approval, and expire five years from the initial exercise date.¹ Separately, the company agreed to amend existing May 2024 warrants covering 520,833 shares, cutting the exercise price from $9.60 to $0.85 per share, an amendment that requires stockholder approval and would expire five years after that approval is obtained.¹ The 8-K identifies the counterparty on those existing warrants as Armistice Capital Master Fund Ltd., under an amendment dated July 16, 2026.

Closing is expected on or about July 17, 2026, subject to customary conditions, with net proceeds slated for working capital and general corporate purposes.¹ A.G.P./Alliance Global Partners is serving as sole placement agent¹, and the company agreed to pay the placement agent a cash fee equal to 6.50% of gross proceeds.¹

Under the purchase agreement, VivoSim agreed to file a registration statement with the SEC covering resale of the shares and warrant shares sold in the offering.¹ The company also agreed, with certain exceptions, not to issue or announce further common stock or equivalents from the agreement date until 60 days after that resale registration statement is declared effective.¹

VivoSim describes itself as a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models of liver and intestine, offering partners toxicology insights through its NAM models.¹